Genetically engineered MSCs kill metastatic lung cancer cells in mice

May 19, 2009

Researchers in London have demonstrated the ability of adult stem cells from bone marrow (mesenchymal stem cells, or MSCs) to deliver a cancer-killing protein to tumors.

The genetically engineered stem cells are able to home to the cancer cells, both in culture and in mouse models, and deliver TNF-related apoptosis-inducing ligand (TRAIL), destroying the tumor cells while sparing normal cells.

The research will be presented on Tuesday, May 19, at the American Thoracic Society's 105th International Conference in San Diego.

"Present oncological therapies are limited by host toxicity," said Michael Loebinger, M.D., M.A, who, along with S. M. Janes, M.D., Ph.D., conducted the research at the Centre for Respiratory Research at the University College of London. "They are also limited by cancer resistance and may not destroy cancer stem cells."

With these experiments, the investigators combined two disparate areas of research that they believed held promise for treating cancer. Studies had shown that MSCs can be used as vectors to deliver anti-tumor therapy, while other studies found that TRAIL killed cancer cells, but not normal cells.

For their experiments, Drs. Loebinger and Janes identified those cells likely to be resistant to therapies (cancer cells that have characteristics of stem cells) and found that they were just as likely to be destroyed as tumor cells by this novel therapy.

In culture, the stem cells caused lung, squamous, breast and cervical cancer cells to die (all p< 0.01), even at low stem cell/tumor cell ratios (1:16).

In mice, the researchers showed that the stem cells could reduce the growth of subcutaneous by approximately 80 percent (p< .0001). the stem cells could also be injected intravenously as therapy for mice with lung and could eliminate lung metastases in 38 percent of mice compared to control mice, all of which still had metastases (p=0.03).

It is the first study to intravenously introduce MSCs that have been genetically modified to deliver TRAIL. Drs. Loebinger and Janes chose the cells for both models because in their in vitro experiments, the MSCs "demonstrated a particularly strong homing to breast ."

"Breast cancer tumors are a good model of metastases," added Dr. Loebinger, "but our plan is to test the engineered with other models, including lung cancer."

While not fully understood, Dr. Loebinger added, the homing of the engineered cells appears to be a characteristic of MSCs themselves.

The authors conclude that, "this is the first study to demonstrate a significant reduction in tumor burden with inducible TRAIL-expressing MSCs in a well-controlled and specifically directed therapy."

They believe that human trials of TRAIL-expressing MSCs could begin in two or three years.

Source: American Thoracic Society (news : web)

Explore further: Researcher to cancer: 'Resistance will be futile'

add to favorites email to friend print save as pdf

Related Stories

Therapy may block expansion of breast cancer cells

Nov 05, 2008

Breast cancer stem cells are known to be involved in therapy resistance and the recurrence of cancerous tumors. A new study appearing in Clinical and Translational Science shows the mechanisms governing stem cell expansion in bre ...

Stem cells as cancer therapy

Dec 26, 2006

It is widely hoped that neural stem cells will eventually be useful for replacing nerves damaged by degenerative diseases like Alzheimer disease and multiple sclerosis. But there may also be another use for such stem cells--delivering ...

Scientists isolate cancer stem cells

Sep 11, 2008

After years of working toward this goal, scientists at the OU Cancer Institute have found a way to isolate cancer stem cells in tumors so they can target the cells and kill them, keeping cancer from returning.

Herceptin targets breast cancer stem cells

Jul 09, 2008

A gene that is overexpressed in 20 percent of breast cancers increases the number of cancer stem cells, the cells that fuel a tumor's growth and spread, according to a new study from the University of Michigan Comprehensive ...

Recommended for you

Researcher to cancer: 'Resistance will be futile'

2 hours ago

Turning the tables, Katherine Borden at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC) has evoked Star Trek's Borg in her fight against the disease. "Cancer cells rapidly ...

How does prostate cancer form?

5 hours ago

Prostate cancer affects more than 23,000 men this year in the USA however the individual genes that initiate prostate cancer formation are poorly understood. Finding an enzyme that regulates this process ...

Low risk of malignancy for small complex adnexal masses

11 hours ago

(HealthDay)—For older women with small complex adnexal masses, the overall risk of malignancy is low, according to a study published in the December issue of the American Journal of Obstetrics & Gynecology.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.